rare disease treatment
Intellia Stock Rises on FDA Clearance for CRISPR Therapy
NTLA performance by TradingView Intellia Therapeutics (NASDAQ: NTLA) saw shares rise after the FDA lifted a clinical hold on one of its Phase 3 trials for nexiguran ziclumeran (nex-z), a CRISPR-based therapy for transthyretin amyloidosis (ATTR). What Happened Last October, U.S. regulators paused two trials after a participant died from severe liver toxicity. The cleared…
